Predictors and significance of histologic response to neoadjuvant therapy for gastric cancer

Background Perioperative therapy is the standard‐of‐care for locally‐advanced gastric cancer but many patients do not respond. There are currently no known factors that predict response to therapy. Methods This was a retrospective study aimed to evaluate treatment effect grade (TEG) in patients with...

Full description

Saved in:
Bibliographic Details
Published in:Journal of surgical oncology 2021-05, Vol.123 (8), p.1716-1723
Main Authors: Rajabnejad, Ataollah, Vaida, Florin, Valasek, Mark, Razzaque, Saqib, Fanta, Paul, Horgan, Santiago, Bouvet, Michael, Lowy, Andrew M., Kelly, Kaitlyn J.
Format: Article
Language:English
Subjects:
Cancer therapies
gastric adenocarcinoma
Gastric cancer
histologic response
Histology
neoadjuvant therapy
Perioperative care
perioperative therapy
treatment effect grade
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Perioperative therapy is the standard‐of‐care for locally‐advanced gastric cancer but many patients do not respond. There are currently no known factors that predict response to therapy. Methods This was a retrospective study aimed to evaluate treatment effect grade (TEG) in patients with locally advanced gastric cancer treated with neoadjuvant therapy and surgery at a single center. Ordinal logistic regression was performed to identify predictors of TEG, scaled from 0 to 3. Results Fifty patients were identified. The majority were male (n = 33) and 50% were Hispanic. The most common regimens given were: 5‐fluorouracil/leucovorin, oxaliplatin, and docetaxel (n = 23, 46%), epirubicin, cis‐ or oxaliplatin, and 5‐fluorouracil/leucovorin or Xeloda (n = 8, 16%), and 5‐fluorouracil/leucovorin and oxaliplatin (n = 9, 18%). Twenty‐seven patients (55%) had complete or partial response to therapy (TEG 0–2), and 23 patients (46%) had no response (TEG 3). Of numerous variables analyzed, only race and SRC histology were associated with TEG. TEG was associated with disease free, but not disease specific survival. Conclusions In this cohort, 46% of patients had no histologic response to therapy. SRC histology, and possibly race, should be considered in determination of optimal multidisciplinary regimens and in amount of therapy to be given upfront, as patients with SRC histology and those of non‐Asian race are less likely to respond to standard regimens.
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.26458